Compare TG Therapeutics Inc (TGTX) vs Vital Farms Inc (VITL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
TG Therapeutics Inc vs Vital Farms Inc — how do they compare? TG Therapeutics Inc trades at $54 (market cap $8.26B), while Vital Farms Inc trades at $13.16 (market cap $590.45M). The key difference: TG Therapeutics Inc is far larger — about 14× Vital Farms Inc's market cap, and TG Therapeutics Inc is trading nearer its 52-week high, Vital Farms Inc nearer its low. Which is the better fit depends on your goals.
| TGTX | VITL | |
|---|---|---|
Market Cap | $8.26B | $590.45M |
Sector | Health | Consumer Staples |
52-Week High | $59.06 | $52.41 |
52-Week Low | $26.39 | $8.28 |
Enterprise Value | $8.50B | $593.26M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TG Therapeutics (TGTX) trades at $53.96, down 1.6% today, with a bullish technical signal and strong profitability metrics including a 65.95% net income margin. Recent news highlights clinical progress, including a Phase 2 trial for Briumvi in schizophrenia (Zacks Investment Research, 2026-07-07) and positive Phase 1 data for subcutaneous Briumvi (GlobeNewsWire, 2026-06-03). However, earnings misses in Q4 2025 and Q1 2026 and a shareholder investigation (PRNewsWire, 2026-07-21) introduce volatility.
The outlook is mixed: analyst consensus is strongly bullish (84.6% buy ratings) with a $48.50 price target, but near-term risks from legal scrutiny and earnings inconsistency warrant caution. Upside hinges on successful drug trials and sales growth, while downside risks include legal outcomes and competitive pressures in the biotech sector.
Vital Farms (VITL) trades at $13.76, up 1.55% on the day, with a bullish technical signal from moving averages. The stock shows strong profitability with a 15.44% ROE and trades at a modest P/E of 13.25. Recent earnings have been mixed, with a Q3 2025 beat but Q1 2026 miss, while analyst sentiment remains positive with 56% buy ratings. Net cash flow is negative due to significant investing activities, and a class action lawsuit filed in May 2026 adds legal overhang.
The outlook is cautiously optimistic given solid fundamentals and analyst support, but near-term performance hinges on reversing negative earnings surprises and managing legal risks. The consensus price target of $13.50 suggests limited upside from current levels, with execution on revenue growth and margin stabilization key to driving shareholder value.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →About Vital Farms Inc
Vital Farms is a leading provider of ethically produced, pasture-raised eggs and butter in the United States. Operating as a Public Benefit Corporation, it manages a network of over 650 family farms to deliver high-welfare food products. It leverages a scalable 'asset-light' partnership model that prioritizes transparency and animal welfare to meet the growing consumer demand for clean-label and sustainable food sources.
Read more on VITL →
